Skip to main content

Table 1 Summarized characteristics of the patients

From: Retrospective analysis of the success and safety of Gold Micro Shunt Implantation in glaucoma

Agea

Glaucoma

Previous interventionsb

Cup-disc ratio

Baseline IOPc

End IOPd

Follow up months

Next intervention

Outcomee

70

Sec

P-T1

0.95

57 (4)

24 (0)

5.8

T

F(3)

70

POAG

none

0.80

34 (3)

44 (1)

8.9

T

F(1,3)

70

PEX

P

1.00

40 (3)

39 (3)

1.4

T

F(3)

60

POAG

none

0.95

16 (3)

21 (4)

2.2

T

F(3)

60

POAG

none

1.00

34 (0)

32 (3)

5.8

T

F(3)

80

POAG

P

0.85

18 (1)

17 (3)

5.0

T

F(3)

60

POAG

none

1.00

34 (0)

30 (3)

5.3

T

F(3)

70

POAG

P

0.80

17 (0)

17 (3)

7.9

T

F(1,3)

40

POAG

none

0.40

32 (4)

33 (1)

1.6

T

F(3)

80

CAG

P-C2

1.00

36 (2)

28 (3)

5.9

T

F(3)

30

POAG

T3-C1

0.95

17 (3)

18 (4)

2.8

T

F(3)

70

CAG

P-I-C3

1.00

28 (5)

17 (3)

3.4

T

F(3)

80

PEX

T3

1.00

26 (1)

44 (1)

9.3

T

F(1,3)

40

Pigment

none

0.90

30 (2)

29 (1)

4.5

T

F(3)

70

PEX

none

0.95

30 (4)

42 (1)

18.0

T

F(1,3)

80

CAG

P-I

0.80

25 (4)

28 (4)

1.0

T

F(3)

30

Sec

P

0.95

28 (2)

25 (0)

37.1

T-GMS ex

F(1,2,3)

50

POAG

none

1.00

16 (1)

17 (1)

12.2

T-GMS ex

F(1,3)

60

POAG

P-A-T2

1.00

20 (3)

34 (0)

1.2

T-GMS ex

F(3)

60

Sec

P-T1

1.00

24 (2)

50 (1)

14.2

B

F(1,3)

60

POAG

P-A3-T2

1.00

20 (1)

21 (2)

9.0

B

F(1,3)

80

PEX

P-T1

0.95

43 (1)

32 (0)

1.3

B

F(3)

60

Sec

C1

0.60

40 (5)

46 (1)

0.5

Cryo

F(3)

60

PEX

TA

0.40

27 (2)

28 (1)

5.3

P-GMS ex

F(2,3)

60

POAG

none

0.75

15 (0)

14 (0)

18.5

GMS ex

F(1,2,3)

60

POAG

none

0.80

14 (1)

12 (0)

12.2

GMS ex

F(1,2,3)

40

POAG

none

0.85

17 (0)

18 (2)

21.6

None

F(1)

50

POAG

T1

1.00

12 (2)

19 (0)

6.7

None

F(1)

50

POAG

T1

0.95

26 (0)

26 (0)

41.3

None

F(1)

40

Pigment

B-T1

0.80

20 (2)

24 (2)

6.6

None

F(1)

60

POAG

P

0.85

28 (5)

14 (0)

46.1

None

success

  1. aAge in years when implanted (rounded half to even for de-identification).
  2. bPrevious interventions with number of interventions.
  3. cBaseline IOP (mmHg) on the day before GMS+ implantation (sum of different active ingredients in IOP lowering therapy).
  4. dIOP at the end of the follow-up (mmHg) (sum of different active ingredients in IOP lowering therapy).
  5. eOutcome of GMS+ implant; F, failure (criteria met), for details see Methods.
  6. Abbreviations: Sec secondary glaucoma, P pseudophakic, T trabeculectomy with mitomycin C, I iridectomy, C cyclodestructive intervention, TA trabecular aspiration, A argon laser trabeculoplasty, B Baerveldt implantation, GMS ex GMS+ explantation, Cryo Cryotherapy.